An Exploratory Open-Label Phase 2 Study of EPI-743 (Vincerinone) in Children With Autism Spectrum Disorder

Trial Profile

An Exploratory Open-Label Phase 2 Study of EPI-743 (Vincerinone) in Children With Autism Spectrum Disorder

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2015

At a glance

  • Drugs Vatiquinone (Primary)
  • Indications Pervasive child development disorders
  • Focus Therapeutic Use
  • Sponsors Edison Pharmaceuticals
  • Most Recent Events

    • 09 Mar 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 07 Oct 2014 Planned End Date changed from 1 Dec 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
    • 07 Oct 2014 Planned primary completion date changed from 1 Oct 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top